A wealth of data indicates that certain genetic abnormalities can target specific cytotoxic drugs and intervene at an early step as a mechanism of resistance in the treatment of non-small-cell lung cancer. Therefore prescribing
E. Felip, MD
Advertisement
Articles by E. Felip, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Anticipated Data and Practice-Changing Trials: An ASCO 2026 Breast Cancer Preview
2
Concomitant COVID-19 Vaccination Tied to Improved OS With Immunotherapy
3
FDA Approves FoundationOne CDx for Tepotinib in MET+ NSCLC
4
Navigating CAR T-Cell Therapy Use as a “Team Sport” in Multiple Myeloma
5